Clinical Trial Update: Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the drug candidate 611 in Chinese adults with moderate to severe chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• 611

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED